PL3043803T3 - Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie - Google Patents
Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanieInfo
- Publication number
- PL3043803T3 PL3043803T3 PL14844012.6T PL14844012T PL3043803T3 PL 3043803 T3 PL3043803 T3 PL 3043803T3 PL 14844012 T PL14844012 T PL 14844012T PL 3043803 T3 PL3043803 T3 PL 3043803T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleotide
- nucleoside compositions
- nucleoside
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876473P | 2013-09-11 | 2013-09-11 | |
| US201461923317P | 2014-01-03 | 2014-01-03 | |
| US201461986577P | 2014-04-30 | 2014-04-30 | |
| PCT/US2014/054930 WO2015038596A1 (en) | 2013-09-11 | 2014-09-10 | Nucleotide and nucleoside compositions and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3043803T3 true PL3043803T3 (pl) | 2022-11-07 |
Family
ID=52666219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14844012.6T PL3043803T3 (pl) | 2013-09-11 | 2014-09-10 | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10149859B2 (pl) |
| EP (2) | EP3043803B1 (pl) |
| JP (4) | JP6762873B2 (pl) |
| DK (1) | DK3043803T3 (pl) |
| ES (1) | ES2927955T3 (pl) |
| HR (1) | HRP20220911T1 (pl) |
| LT (1) | LT3043803T (pl) |
| PL (1) | PL3043803T3 (pl) |
| SI (1) | SI3043803T1 (pl) |
| TW (1) | TW201542581A (pl) |
| UY (1) | UY35732A (pl) |
| WO (1) | WO2015038596A1 (pl) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013265194B2 (en) | 2012-05-25 | 2018-01-04 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
| CA2891266C (en) | 2012-11-16 | 2020-12-08 | University College Cardiff Consultants Limited | Gemcitabine phosphate mixture for the treatment of cancer |
| PL3043803T3 (pl) * | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| CA3207106A1 (en) * | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PT3160978T (pt) | 2014-06-25 | 2020-08-24 | NuCana plc | Profármacos de gemcitabina |
| SG10202009020VA (en) * | 2014-11-28 | 2020-10-29 | NuCana plc | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
| JP6735751B2 (ja) * | 2014-12-15 | 2020-08-05 | エモリー ユニバーシティー | Ｂ型肝炎ウイルスの治療のためのホスホルアミデート |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| WO2016144918A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| CA2997170A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
| CN106674297A (zh) * | 2015-11-11 | 2017-05-17 | 中国科学院生态环境研究中心 | 具有抗癌活性的新型krn7000类似物及合成方法 |
| WO2017155923A1 (en) * | 2016-03-07 | 2017-09-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| BR112019003946A2 (pt) | 2016-08-31 | 2019-05-21 | Fujifilm Corporation | agente antitumoral, reforçador do efeito antitumoral e kit antitumoral |
| SG11201901457TA (en) | 2016-09-07 | 2019-03-28 | Atea Pharmaceuticals Inc | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| WO2018110678A1 (ja) * | 2016-12-16 | 2018-06-21 | 国立大学法人岐阜大学 | ヌクレオシド誘導体及びその利用 |
| SG10202012214WA (en) | 2017-02-01 | 2021-01-28 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| US10688112B2 (en) | 2017-07-13 | 2020-06-23 | Emory University | Lipid disulfide prodrugs and uses related thereto |
| WO2019088179A1 (ja) | 2017-10-31 | 2019-05-09 | ヤマサ醤油株式会社 | ヌクレオシド誘導体及びその利用 |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| PH12022550371A1 (en) | 2017-12-07 | 2023-05-03 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2019133712A1 (en) | 2017-12-27 | 2019-07-04 | Schinazi Raymond F | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents |
| EP3763724A4 (en) * | 2018-03-09 | 2022-01-12 | Japan Science and Technology Agency | SS-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, SS-MODIFIED PHOSPHORIC ACID COMPOUND, RESPONSE INHIBITOR AND DRUG THEREOF, AND RESPONSE INHIBITION METHOD |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| CN110655546B (zh) * | 2018-12-18 | 2023-05-16 | 安徽贝克制药股份有限公司 | 索非布韦衍生物及其制备方法和应用 |
| CN109503688A (zh) * | 2018-12-21 | 2019-03-22 | 佛山科学技术学院 | 具有抑制病毒复制活性的核苷磷酸长链酯类似物、制备方法及其药物用途 |
| CN113710680B (zh) * | 2019-04-05 | 2025-01-24 | 株式会社日本触媒 | 交联型人工核苷的制备 |
| CN110204584B (zh) * | 2019-06-17 | 2022-09-09 | 大连大学 | 一种4-s-2’,3’,5’-o-三乙酰基尿苷合成方法 |
| CN110105416B (zh) * | 2019-06-17 | 2022-07-12 | 大连大学 | 一种4-S-5-Br-2’，3’,5’-O-三乙酰基尿苷合成方法 |
| CN114502172A (zh) | 2019-08-22 | 2022-05-13 | 爱默蕾大学 | 核苷前药及其相关用途 |
| IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR20220143064A (ko) | 2020-02-18 | 2022-10-24 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR102145197B1 (ko) * | 2020-03-10 | 2020-08-18 | 부광약품 주식회사 | 코로나바이러스를 치료하기 위한 l-뉴클레오사이드의 용도 |
| KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| WO2022081823A1 (en) * | 2020-10-14 | 2022-04-21 | Temple University -Of The Commonwealth System Of Higher Education | Pharmacologic approach for suppression of coronaviruses |
| CN112778356B (zh) * | 2020-12-26 | 2022-07-01 | 山东日兴新材料股份有限公司 | 一种三(三溴新戊基)磷酸酯阻燃剂的一锅法合成工艺 |
| CN112661802B (zh) * | 2021-01-25 | 2022-05-13 | 阿里生物新材料（常州）有限公司 | 一种3′-甲氧基鸟苷的合成方法 |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| EP4323362B1 (en) | 2021-04-16 | 2025-05-07 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
| WO2022235874A1 (en) * | 2021-05-05 | 2022-11-10 | Emory University | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
| AR126073A1 (es) | 2021-06-04 | 2023-09-06 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio |
| CN113278041B (zh) * | 2021-07-16 | 2021-10-19 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN113501853B (zh) * | 2021-09-13 | 2021-12-07 | 南京颐媛生物医学研究院有限公司 | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 |
| CN113735927B (zh) * | 2021-10-18 | 2024-06-28 | 厦门蔚扬药业有限公司 | 一种核苷酸类似物及其制备方法和用途 |
| WO2023086557A1 (en) * | 2021-11-11 | 2023-05-19 | Emory University | Nucleosides for the treatment of dna virus infections |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| WO2023146974A2 (en) * | 2022-01-26 | 2023-08-03 | The Regents Of The University Of California | Antiviral prodrugs, intermediate- and long-acting formulations and methods |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| KR20250004956A (ko) | 2022-03-15 | 2025-01-08 | 롬 테라퓨틱스, 인크. | 질환을 치료하기 위한 화합물 및 방법 |
| EP4493198A1 (en) * | 2022-03-16 | 2025-01-22 | Pharmalectin, Inc. | Lectin-binding carbohydrates for treating viral infections |
| EP4248949B1 (en) | 2022-03-21 | 2024-08-28 | R.G.C.C. Holdings AG | Liposomal compositions |
| CN117321066A (zh) * | 2022-07-12 | 2023-12-29 | 南京工业大学 | 一种基于虫草素经衍生化具有抗肿瘤效应的化合物 |
| WO2024137577A1 (en) * | 2022-12-19 | 2024-06-27 | Ohio State Innovation Foundation | Multiparametric integrated molecular detection of viral antigens and viral nucleic acids |
| WO2024167952A1 (en) * | 2023-02-08 | 2024-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oxidatively cleavable organophosphate drugs |
| US20240390408A1 (en) * | 2023-05-26 | 2024-11-28 | Altesa BioSciences, Inc. | Method of treating hepatitis c virus in patients |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3404144A (en) * | 1965-12-23 | 1968-10-01 | Research Corp | 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds |
| DE2041735A1 (de) * | 1970-08-22 | 1972-02-24 | Merck Patent Gmbh | Thio-pyrimidin-derivate |
| US3975374A (en) * | 1970-12-21 | 1976-08-17 | The Upjohn Company | Process for preparing 2-thiouracil nucleosides |
| JPS4947379A (pl) * | 1972-09-12 | 1974-05-08 | ||
| PL107865B1 (pl) | 1977-04-27 | 1980-03-31 | Polska Akademia Nauk Instytut | Method of obtaining styrene oxide sposob otrzymywania tlenku styrenu |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US4954485A (en) * | 1987-10-20 | 1990-09-04 | Sanyo-Kokusaku Pulp Co., Ltd. | 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| EP1655033A1 (en) | 1995-06-07 | 2006-05-10 | Emory University | Nucleosides with anti-hepatitis B virus activity |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| JPH107694A (ja) * | 1996-06-21 | 1998-01-13 | Toagosei Co Ltd | ３’−アミノ−２−チオピリミジンヌクレオシド |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6610835B1 (en) | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6461422B1 (en) * | 2000-01-27 | 2002-10-08 | Chartpak, Inc. | Pressure sensitive ink jet media for digital printing |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| BR0111196A (pt) * | 2000-05-26 | 2004-04-06 | Idenix Cayman Ltd | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CN1482914A (zh) * | 2000-12-26 | 2004-03-17 | 三菱制药株式会社 | 丙型肝炎治疗剂 |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| PL197669B1 (pl) * | 2002-02-28 | 2008-04-30 | Pan Inst Biochemii I Biofizyki | Nowe analogi 2',3'-dideoksy-3'-fluorotymidyny o aktywności przeciwko wirusom (54) ludzkiego niedoboru immunologicznego HIV-1 i HIV-2, sposób ich wytwarzania oraz zawierające je środki farmaceutyczne |
| CN1653077A (zh) | 2002-05-06 | 2005-08-10 | 健亚生物科技公司 | 治疗c型肝炎病毒感染的核苷衍生物 |
| CN103275159A (zh) | 2002-06-28 | 2013-09-04 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
| US20040035547A1 (en) | 2002-08-20 | 2004-02-26 | 3M Innovative Properties Company | Metal matrix composites, and methods for making the same |
| US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| CA2633757A1 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| PL2203430T3 (pl) | 2007-09-17 | 2011-12-30 | Abbvie Bahamas Ltd | N-fenylo-diokso-hydropirymidyny użyteczne jako inhibitory wirusa zapalenia wątroby typu C (HCV) |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
| ES2413080T3 (es) | 2009-03-25 | 2013-07-15 | Abbvie Inc. | Compuestos antivirales y usos de los mismos |
| WO2010111436A2 (en) | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
| SG175144A1 (en) | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| ES2511440T3 (es) | 2009-06-11 | 2014-10-22 | Abbvie Bahamas Ltd. | Compuestos antivirales para tratar la infección por el VHC |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| BR112012022774A2 (pt) | 2010-03-10 | 2017-09-12 | Abbott Lab | Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas |
| WO2011133580A1 (en) * | 2010-04-19 | 2011-10-27 | Back Bay Scientific Llc | Use of drugs that activate p2y receptors to enhance synaptogenesis |
| CN103025736B (zh) | 2010-06-07 | 2016-07-06 | Abbvie公司 | 大环的丙型肝炎丝氨酸蛋白酶抑制剂 |
| SG10201505540SA (en) | 2010-07-16 | 2015-08-28 | Abbott Lab | Process for preparing antiviral compounds |
| EA025341B1 (ru) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
| TWI451439B (zh) | 2010-12-10 | 2014-09-01 | Phison Electronics Corp | 記憶體儲存裝置、其記憶體控制器與資料寫入方法 |
| CN103354808B (zh) | 2010-12-16 | 2016-08-10 | Abbvie公司 | 抗病毒化合物 |
| CA2821973A1 (en) | 2010-12-16 | 2012-06-21 | Abbvie Inc. | Anti-viral compounds |
| US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| EP2755693A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| PL3043803T3 (pl) * | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| JP6735751B2 (ja) * | 2014-12-15 | 2020-08-05 | エモリー ユニバーシティー | Ｂ型肝炎ウイルスの治療のためのホスホルアミデート |
-
2014
- 2014-09-10 PL PL14844012.6T patent/PL3043803T3/pl unknown
- 2014-09-10 ES ES14844012T patent/ES2927955T3/es active Active
- 2014-09-10 HR HRP20220911TT patent/HRP20220911T1/hr unknown
- 2014-09-10 EP EP14844012.6A patent/EP3043803B1/en active Active
- 2014-09-10 EP EP22170131.1A patent/EP4094767A1/en active Pending
- 2014-09-10 US US14/917,681 patent/US10149859B2/en active Active
- 2014-09-10 TW TW103131136A patent/TW201542581A/zh unknown
- 2014-09-10 JP JP2016542060A patent/JP6762873B2/ja active Active
- 2014-09-10 WO PCT/US2014/054930 patent/WO2015038596A1/en active Application Filing
- 2014-09-10 LT LTEPPCT/US2014/054930T patent/LT3043803T/lt unknown
- 2014-09-10 SI SI201431976T patent/SI3043803T1/sl unknown
- 2014-09-10 DK DK14844012.6T patent/DK3043803T3/da active
- 2014-09-11 UY UY0001035732A patent/UY35732A/es active IP Right Grant
-
2018
- 2018-11-21 US US16/198,240 patent/US11166973B2/en active Active
-
2020
- 2020-04-24 JP JP2020077187A patent/JP7045411B2/ja active Active
-
2021
- 2021-10-27 US US17/512,014 patent/US11857560B2/en active Active
-
2022
- 2022-03-17 JP JP2022042207A patent/JP7508501B2/ja active Active
-
2023
- 2023-11-21 US US18/515,989 patent/US20240173345A1/en active Pending
-
2024
- 2024-06-18 JP JP2024097892A patent/JP2024123107A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2927955T3 (es) | 2022-11-14 |
| US11857560B2 (en) | 2024-01-02 |
| HRP20220911T1 (hr) | 2022-10-28 |
| US20190298750A1 (en) | 2019-10-03 |
| JP2024123107A (ja) | 2024-09-10 |
| JP2022081641A (ja) | 2022-05-31 |
| JP7508501B2 (ja) | 2024-07-01 |
| JP2016530313A (ja) | 2016-09-29 |
| EP4094767A1 (en) | 2022-11-30 |
| US20220296626A1 (en) | 2022-09-22 |
| DK3043803T3 (da) | 2022-08-01 |
| TW201542581A (zh) | 2015-11-16 |
| EP3043803B1 (en) | 2022-04-27 |
| JP2020143073A (ja) | 2020-09-10 |
| US20160220595A1 (en) | 2016-08-04 |
| EP3043803A4 (en) | 2017-03-29 |
| US20240173345A1 (en) | 2024-05-30 |
| JP7045411B2 (ja) | 2022-03-31 |
| SI3043803T1 (sl) | 2022-09-30 |
| WO2015038596A1 (en) | 2015-03-19 |
| LT3043803T (lt) | 2022-08-10 |
| US10149859B2 (en) | 2018-12-11 |
| US11166973B2 (en) | 2021-11-09 |
| EP3043803A1 (en) | 2016-07-20 |
| UY35732A (es) | 2015-06-30 |
| JP6762873B2 (ja) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269461B (en) | Cytidine-5-carboxamide modified nucleotide preparations and related methods | |
| SI3043803T1 (sl) | Nukleotidne in nukleozidne sestave in njihova uporaba | |
| IL273205A (en) | Preparations and methods | |
| IL245014B (en) | Nucleosides, modified nucleotides and their analogs | |
| GB2521022B (en) | Compositions and methods | |
| GB201313235D0 (en) | Antiviral Compositions Methods and Animals | |
| AP2015008954A0 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| EP2953474A4 (en) | COMPOSITIONS AND METHODS | |
| GB201308072D0 (en) | Compositions and methods | |
| EP2957567A4 (en) | NUCLEOSIDE AND NUCLEOTIDE WITH AN NITROGENIC HETEROCYCLIC STRUCTURE | |
| GB201321693D0 (en) | Composition and uses thereof | |
| ZA201507045B (en) | Uridine nucleoside derivatives, compositions and methods of use | |
| IL276126B (en) | Preparations containing l-4-chloroquinonerine and their uses | |
| GB201305813D0 (en) | Compositions and methods | |
| EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
| HUE037525T2 (hu) | Kis sejtmagvacska RNS (SNORNA), készítmények és alkalmazások | |
| IL233475A0 (en) | Carbocyclic nucleosides, preparations containing them and their uses | |
| ZA201500493B (en) | Glycoconjugation processes and compositions | |
| GB201308242D0 (en) | Compositions and uses thereof | |
| GB201322617D0 (en) | Methods and compositions | |
| GB201312393D0 (en) | Compositions and Methods | |
| GB201301022D0 (en) | Composition and uses thereof |